

Clinical trials of dalcetrapib

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

| Trial | Treatments | Patients | Trials design and methods |
|--|--|---|---|
| dalcetrapib vs placebo | | | |
| dal-VESSEL , 2011 n=NA follow-up: 12 weeks | dalcetrapib 600 mg daily versus placebo | men and women with coronary heart disease or coronary heart disease risk equivalents with HDL-cholesterol levels <50 mg/dL | Parallel groups double-blind |
| dal-OUTCOMES , 2012 [NCT00658515] n=7938/7933 follow-up: 31 monthsh (median) | dalcetrapib 600 mg daily beginning 4 to 12 weeks after an index ACS event versus placebo | patients with recent acute coronary syndrome | Parallel groups double-blind 27 countries |
| dalcetrapib vs | | | |
| NCT01516541 <i>ongoing</i> [NCT01516541] n=2220 follow-up: | dalcetrapib 600 mg orally daily versus placebo | patients with stable coronary heart disease (CHD), with CHD risk equivalents or at elevated risk for cardiovascular disease | |
| NCT01059682 <i>ongoing</i> [NCT01059682] n=936 follow-up: | dalcetrapib 600 mg orally once a day versus placebo | subjects undergoing coronary angiography who have coronary artery disease | |

More details and results :

- CEPT inhibition for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q340>
- HDL increasing drugs for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q503>

References

dal-VESSEL, 2011:

dal-OUTCOMES, 2012:

Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009 Dec;158:896-901.e3 [19958854]

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. N Engl J Med 2012 Nov 5; [23126252]
[10.1056/NEJMoa1206797](https://doi.org/10.1056/NEJMoa1206797)

NCT01516541, :

ongoing trial NCT01516541

NCT01059682, :

ongoing trial NCT01059682